Impact of previous corticosteroid (CS) exposure on efficacy of programmed cell death-(Ligand) 1 blockade in patients with advanced non-small cell lung cancer (NSCLC): A single center retrospective analysis

Impact of Baseline Corticosteroids on Immunotherapy Efficacy in Patients With Advanced Melanoma

“…6,7 Several retrospective studies assessed the effect of baseline corticosteroid on immunotherapy efficacy in patients with advanced cancer. [8][9][10][11][12][13][14] Results from these studies were conflicting. Notably, 2 recent studies suggested that a baseline prednisone-equivalent of ≥ 10 mg within 30 days of immunotherapy initiation was associated with decreased treatment efficacy in patients with non-small cell lung cancer (NSCLC).…”

“…8,9 A subsequent study suggested similar overall findings but attributed the decreased treatment efficacy to a poor-prognosis subgroup as indicated by palliative-intent corticosteroid use. 10 Moreover, these studies were mainly completed in patients with advanced NSCLC [8][9][10][11][12][13] and genitourinary cancers, 11,14 and only 1 study involved patients with advanced melanoma. 11 The largest study involved 742 patients with advanced melanoma on any line of immunotherapy, with 182 of them received baseline corticosteroid ≤ 14 days prior and up to 30 days after immunotherapy initiation.…”

“…Several retrospective studies assessed the effect of baseline corticosteroid on immunotherapy efficacy in patients with advanced cancer 8–14. Results from these studies were conflicting.…”